Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months
- Conditions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 682
- Registration Number
- NCT05832333
- Locations
- 🇰🇷
Site 006, Gyeongsangnam-do, Korea, Republic of
🇰🇷Site 010, Gyeongsangnam-do, Korea, Republic of
🇰🇷Site 002, Gwangju, Korea, Republic of
A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness
- Conditions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 14799
- Registration Number
- NCT05819112
- Locations
- 🇺🇸
Sanofi U.S., Bridgewater, New Jersey, United States
Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin
- Conditions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 21000
- Registration Number
- NCT05819125
- Locations
- 🇺🇸
Sanofi U.S., Bridgewater, New Jersey, United States
A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)
- Conditions
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT05797753
- Locations
- 🇺🇸
Nucleus Network-Site Number:8400001, Saint Paul, Minnesota, United States
A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)
- Conditions
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT05797701
- Locations
- 🇺🇸
Prism Research-Site Number:8400001, Saint Paul, Minnesota, United States
Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT05795907
- Locations
- 🇺🇸
Prism Research-Site Number:8400001, Saint Paul, Minnesota, United States
A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 32
- Registration Number
- NCT05796479
- Locations
- 🇺🇸
Clinical Pharmacology of Miami-Site Number: 8400001, Hialeah, Florida, United States
Cold Agglutinin Disease Real World Evidence Registry
- Conditions
- Interventions
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 400
- Registration Number
- NCT05791708
- Locations
- 🇺🇸
Mission Hope Medical Oncology Site Number : 1241, Santa Maria, California, United States
🇺🇸Hematology Oncology Associates, PC Site Number : 1211, Medford, Oregon, United States
🇫🇷Investigational Site Number : 3211, CHALON SUR SAONE Cedex, France
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 901
- Registration Number
- NCT05769777
- Locations
- 🇦🇷
Investigational Site Number : 0320022, Gral. Pico, La Pampa, Argentina
🇦🇷Investigational Site Number : 0320007, Rosario, Santa Fe, Argentina
🇦🇷Investigational Site Number : 0320008, Buenos Aires, Argentina
Avalglucosidase Alfa Pregnancy Study
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT05734521
- Locations
- 🇺🇸
Investigational site worldwide, Bridgewater, New Jersey, United States